Processing...
Clinical Trials for Melanoma
Search
Search
There are 161 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
161 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced/metastatic solid tumors after standard therapy receive REGN10597, an intravenously delivered anti–PD-1–IL2RA–IL2 fusion protein designed to target IL-2 signaling to PD-1–positive activated T cells while limiting systemic IL-2 effects; expansion cohorts enroll melanoma and clear-cell RCC. Key exclusions include prior IL-2/IL-15/IL-7 therapy, recent checkpoint inhibitors or systemic therapy, active immune-related AEs, significant autoimmune disease, or need for systemic immunosuppression.
ClinicalTrials.gov ID: NCT06413680
TrialFetch AI summary: Pediatric trial of pembrolizumab (anti–PD-1 monoclonal antibody) monotherapy for children/adolescents with advanced melanoma (currently enrolling ages ≥12–≤18) and biomarker-selected solid tumors (MSI-H or TMB ≥10 mut/Mb), plus a cohort for relapsed/refractory classic Hodgkin lymphoma (ages 3–<18) and an adjuvant cohort for resected high-risk melanoma (ages 12–<18). Key exclusions include prior PD-1/PD-L1/CTLA-4 therapy and active CNS metastases or autoimmune disease; dosing is IV q3 weeks (2 mg/kg, max 200 mg).
ClinicalTrials.gov ID: NCT02332668
TrialFetch AI summary: Enrolls adults with unresectable/metastatic melanoma progressing after PD‑1/PD‑L1 therapy and other checkpoint inhibitor–responsive solid tumors for AB821 monotherapy, an IV CD8‑IL21 fusion immunotherapy that selectively activates IL‑21 signaling in CD8+ T cells to enhance cytotoxicity and T‑cell memory. Patients must have ECOG 0–1 and adequate organ function; key exclusions include active autoimmune disease requiring treatment, untreated/unstable CNS metastases, significant cardiovascular disease, chronic immunosuppression, and prior IL‑21–based therapy.
ClinicalTrials.gov ID: NCT07027488
TrialFetch AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) after standard therapy failure; phase 1 tests oral GIM‑531 monotherapy (including NSCLC, TNBC, platinum‑resistant ovarian, and AKT3‑altered tumors), and phase 2 treats melanoma, NSCLC, or RCC that progressed on anti‑PD‑1 with continued anti‑PD‑1 plus GIM‑531. GIM‑531 is a first‑in‑class, Treg‑selective small‑molecule inhibitor linked to AKT3/PI3K–AKT pathway modulation to suppress Tregs and potentially restore antitumor immunity.
ClinicalTrials.gov ID: NCT06425926
TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors that are refractory/intolerant to standard therapies or lack standard options (ECOG 0–2; no active CNS/leptomeningeal metastases) receive IV JMT108 every 2 weeks (with possible alternate schedules in expansion). JMT108 is a fully human anti–PD-1 antibody fused to IL-15 intended to combine checkpoint blockade with IL-15–driven activation/proliferation of CD8+ T cells and NK cells, with tumor-specific expansion cohorts including lung, colorectal, hepatocellular, gastric cancers, melanoma, and other solid tumors.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Adults with metastatic or unresectable locally advanced NSCLC, esophageal squamous cell carcinoma, or cutaneous melanoma after standard therapy or 1–2 prior systemic regimens receive IV PF-08046033 in 21-day cycles. PF-08046033 is an investigational GPNMB-directed antibody-drug conjugate delivering auristatin S to GPNMB-expressing tumor cells, with dose escalation followed by tumor-specific expansion cohorts.
ClinicalTrials.gov ID: NCT07519655
TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic melanoma or advanced non-small-cell lung cancer who have progressed after at least anti-PD-1/PD-L1 therapy, using an autologous tumor-infiltrating lymphocyte product (IOV-4001) genetically edited to knock out PD-1 via TALEN technology, administered after lymphodepleting chemotherapy and followed by high-dose IL-2. PD-1 knockout aims to enhance TIL antitumor activity by reducing exhaustion.
ClinicalTrials.gov ID: NCT05361174
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.
ClinicalTrials.gov ID: NCT05107674
TrialFetch AI summary: This study enrolls adults with unresectable, locally advanced, or metastatic antigen-rich solid tumors—including TMB-H, MSI-H/dMMR, virally associated, metastatic colorectal, triple negative breast, platinum-resistant ovarian, metastatic castration-resistant prostate, and NSCLC—who lack standard treatment options. Patients receive STAR0602 (invikafusp alfa), a bifunctional bispecific antibody that selectively activates and expands Vβ6/Vβ10 T cell subsets to enhance antitumor immunity.
ClinicalTrials.gov ID: NCT05592626
TrialFetch AI summary: Adults with measurable, biopsy-accessible stage III (macroscopic nodal) or stage IV melanoma, ECOG 0–1, and no prior PD‑1/PD‑L1 or CTLA‑4 therapy receive ipilimumab plus nivolumab combined with CBL0137, a non-genotoxic DNA intercalator that traps FACT to activate p53 and suppress NF‑κB/HSF1/MYC. Excludes active autoimmune disease or need for immunosuppression; serial biopsies and blood draws required.
ClinicalTrials.gov ID: NCT05498792